Kezar Life Sciences Inc expected to post a loss of $3.15 a share - Earnings Preview

Kezar Life Sciences

11/11/2024 15:33

* Kezar Life Sciences Inc  KZR.OQ   KZR.O  is expected
to show a
fall in quarterly revenue when it reports  results on November
13 (estimated) for the period ending January 1 0001
    * The South San Francisco California-based  company is
expected to
report a 88.6% decrease in revenue to $800 thousand from $7
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Kezar Life Sciences Inc
is for
a loss of $3.15 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kezar Life
Sciences Inc is $25.00​, above​ its last closing price of $7.37.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -3.39       -3.20      -2.70     Beat    15.7
 Jan. 1 2024   -3.33       -3.33      -3.00     Beat    9.9
 Dec. 31 2023  -4.30       -3.80      -4.40     Missed  -15.8​
 Sep. 30 2023  -3.58       -3.49      -3.20     Beat    8.4
 ​​Jan.        -3.21       -3.20      -3.40     Missed  -6.2
 1 0001                                                 
 Mar. 31 2023  -2.90       -2.88      -3.10     Missed  -7.5​
 Dec. 31 2022              -2.76      -2.50     Beat    9.6
 Sep. 30 2022  -2.71       -2.70      -2.50     Beat    7.5
 This summary was machine generated November 11 at 15:32 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)